Study of CHO-H01 for certain relapsed lymphoma, alone or with lenalidomide
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests CHO-H01 (an anti-cancer medicine targeting CD20) to see if it is safe and effective in people with relapsed or refractory non-Hodgkin’s lymphoma. In one part of the study it may be used alone, and in another part it may be combined with lenalidomide to improve results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be expected to live at least 12 weeks.
- Your body weight measure (BMI) must be between 18 and 32.
- Your lymphoma must be CD20-positive based on lab testing, and your type must match the study’s allowed subtypes.
- You need at least one lymphoma spot that can be measured and is at least 1.5 cm at the largest point.
- You must be off certain lymphoma infusions for at least 30 days before starting CHO-H01, and be willing to get a biopsy if needed.
- Your heart health must be adequate, and you must use strict pregnancy prevention during the study and for a period after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
This early-phase study tests a new treatment called STR-P004 for people with certain aggressive B-cell lymphomas that have not responded to or returned after two or more prior treatments. The goal is to see if it is safe and effective.
This trial tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) for people with diffuse large B-cell lymphoma that has come back or not responded to earlier treatment. It aims to see if this new mix can help when standard therapies have stopped working.
This trial tests a combination of three drugs for people with a slow-growing form of non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to see if this new combination can help shrink tumors or slow the disease.
This Phase 1 study tests an investigational treatment for adults with lymphoma that has come back or did not respond to prior treatments. It targets lymphoma cells that have CD19 and CD20 markers, aiming to reduce or control the disease in people with limited options.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.